Alexion Pharmaceuticals (NASDAQ:ALXN)‘s stock had its “outperform” rating reissued by equities researchers at Raymond James Financial in a research note issued on Thursday. They presently have a $130.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $178.00. Raymond James Financial’s target price would suggest a potential upside of 5.86% from the stock’s previous close. The analysts noted that the move was a valuation call.
Several other brokerages have also issued reports on ALXN. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective on the stock in a report on Tuesday, October 31st. BidaskClub raised Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Leerink Swann reaffirmed an “outperform” rating and set a $182.00 price objective (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. They noted that the move was a valuation call. Credit Suisse Group reissued a “buy” rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a report on Tuesday, December 12th. Finally, Stifel Nicolaus lowered their price target on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a report on Tuesday, October 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and twenty have issued a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $153.61.
Alexion Pharmaceuticals (ALXN) opened at $122.80 on Thursday. The stock has a market capitalization of $27,430.00, a PE ratio of 54.82, a price-to-earnings-growth ratio of 1.05 and a beta of 1.17. Alexion Pharmaceuticals has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.23 earnings per share. sell-side analysts forecast that Alexion Pharmaceuticals will post 4.82 EPS for the current year.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the sale, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.35% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jennison Associates LLC lifted its position in shares of Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after acquiring an additional 4,682,336 shares during the period. HPM Partners LLC lifted its position in shares of Alexion Pharmaceuticals by 267.2% during the 2nd quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock valued at $656,000 after acquiring an additional 4,861 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Alexion Pharmaceuticals by 4,509.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after acquiring an additional 864,967 shares during the period. Principal Financial Group Inc. lifted its position in shares of Alexion Pharmaceuticals by 1.2% during the 2nd quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock valued at $40,823,000 after acquiring an additional 4,115 shares during the period. Finally, USA Financial Portformulas Corp acquired a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter valued at approximately $3,632,000. 94.26% of the stock is currently owned by institutional investors.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.